We are live on ! Find out more
Grandfield & Dodd

Grandfield & Dodd Portfolio holdings

AUM $1.87B Turnover 5.83%
1-Year Est. Return 27.26%
 

Grandfield & Dodd is an independently owned investment counsel firm that builds portfolios of individual stocks and bonds for individuals, families and trusts. Cheryl Grandfield, a former partner at Brundage, Story & Rose, started it in 2001 with Richard Dodd, who had been a senior portfolio manager of tax-exempt bonds at The Bank of New York, and James Samuels. They saw a gap as investment managers moved toward standardised pooled products, and aimed at clients who preferred owning individual securities directly. On stocks, the firm looks at companies as a business owner would and favours industry leaders, while keeping its holdings spread across industries and securities. Its bond holdings lean toward higher quality and shorter maturities, which limits how far prices swing when interest rates change.

This Fund
S&P 500
This Quarter Est. Return
+1.18%
1 Year Est. Return
+27.26%
3 Year Est. Return
+80.65%
5 Year Est. Return
+95.39%
10 Year Est. Return
+347.34%
AUM
$1.87B
AUM Growth
-$33M
Cap. Flow
+$3.63M
Cap. Flow %
0.19%
Top 10 Hldgs %
38.52%
Holding
223
New
6
Increased
53
Reduced
70
Closed
7
Avg Time Held
7.8 years
Top 10 Avg Time Held
4.5 years
Top 20 Avg Time Held
6 years

Top Buys

Rank Stock Value
1
BA icon
Boeing
BA
+$4.72M
2
AOS icon
A.O. Smith
AOS
+$2.6M
3
CSL icon
Carlisle Companies
CSL
+$2.36M
4
VLTO icon
Veralto
VLTO
+$1.71M
5
ADSK icon
Autodesk
ADSK
+$1.17M

Sector Composition

Rank Sector Weight
1 Technology 31.78%
2 Industrials 19.46%
3 Healthcare 14.71%
4 Financials 8.44%
5 Materials 7.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
HUBB icon
101
Hubbell
HUBB
$22.5B
$1.4M 0.07%
3,095
– –
2015 Q4
43 quarters
PFE icon
102
Pfizer
PFE
$160B
$1.39M 0.07%
48,815
+1,094
+2% +$29.1K
2013 Q2
53 quarters
ISRG icon
103
Intuitive Surgical
ISRG
$146B
$1.34M 0.07%
3,296
-150
-4% -$57.3K
2013 Q4
51 quarters
GMAB icon
104
Genmab
GMAB
$31.4B
$1.34M 0.07%
37,538
-95
-0.3% -$3K
2022 Q3
16 quarters
RSP icon
105
Invesco S&P 500 Equal Weight ETF
RSP
$102B
$1.3M 0.07%
6,237
+371
+6% +$80.2K
2024 Q1
10 quarters
V icon
106
Visa
V
$775B
$1.21M 0.06%
3,368
-10
-0.3% -$3.66K
2015 Q2
45 quarters
IVW icon
107
iShares S&P 500 Growth ETF
IVW
$70.8B
$1.2M 0.06%
8,430
– –
2025 Q2
5 quarters
HD icon
108
Home Depot
HD
$337B
$1.14M 0.06%
4,023
-300
-7% -$98.5K
2013 Q2
53 quarters
BMRN icon
109
BioMarin Pharmaceuticals
BMRN
$11.9B
$1.13M 0.06%
18,872
+629
+3% +$39.6K
2014 Q4
47 quarters
ETN icon
110
Eaton
ETN
$131B
$1.13M 0.06%
2,631
– –
2020 Q4
23 quarters
UNP icon
111
Union Pacific
UNP
$179B
$1.12M 0.06%
4,103
– –
2013 Q2
53 quarters
VV icon
112
Vanguard Morningstar Large-Cap ETF
VV
$51.9B
$1.04M 0.06%
2,955
-2,675
-48% -$936K
2018 Q3
32 quarters
CSCO icon
113
Cisco
CSCO
$383B
$981K 0.05%
9,111
-631
-6% -$71.1K
2015 Q2
45 quarters
DE icon
114
Deere & Co
DE
$174B
$966K 0.05%
1,439
– –
2026 Q1
2 quarters
VPL icon
115
Vanguard FTSE Pacific ETF
VPL
$7.94B
$966K 0.05%
8,340
– –
2013 Q2
53 quarters
FCX icon
116
Freeport-McMoran
FCX
$73.8B
$946K 0.05%
13,519
– –
2013 Q2
53 quarters
IOVA icon
117
Iovance Biotherapeutics
IOVA
$3.46B
$926K 0.05%
62,500
-20
-0% -$143
2024 Q3
8 quarters
VEA icon
118
Vanguard FTSE Developed Markets ETF
VEA
$220B
$877K 0.05%
12,423
– –
2020 Q3
24 quarters
EFA icon
119
iShares MSCI EAFE ETF
EFA
$74.4B
$868K 0.05%
8,355
– –
2020 Q1
26 quarters
TSLA icon
120
Tesla
TSLA
$1.52T
$868K 0.05%
2,445
– –
2020 Q2
25 quarters
VWO icon
121
Vanguard FTSE Emerging Markets ETF
VWO
$114B
$861K 0.05%
14,516
– –
2025 Q2
5 quarters
GLD icon
122
SPDR Gold Trust
GLD
$125B
$858K 0.05%
2,254
– –
2025 Q2
5 quarters
ORCL icon
123
Oracle
ORCL
$355B
$855K 0.05%
6,230
-100
-2% -$14.1K
2013 Q2
53 quarters
VO icon
124
Vanguard Morningstar Mid-Cap ETF
VO
$105B
$854K 0.05%
10,892
+145
+1% +$11.8K
2018 Q3
32 quarters
ALNY icon
125
Alnylam Pharmaceuticals
ALNY
$20B
$834K 0.04%
3,379
+175
+5% +$44.5K
2024 Q3
8 quarters

Similar funds

Grandfield & Dodd's Q3 2026 Portfolio in Review

As of Q3 2026, Grandfield & Dodd held 223 positions worth $1.87B, down 1.7% from $1.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Grandfield & Dodd's Q3 2026 filing shows 6 new, 53 increased, 70 reduced and 7 closed positions. Its largest new stake was Carlisle Companies: 6,797 shares worth $2.19M. The largest sale was Applied Materials, an estimated $3.25M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 32% a quarter earlier, followed by Industrials and Healthcare.

  • Grandfield & Dodd's largest Q3 2026 buy was Carlisle Companies: 6,797 shares worth $2.19M.
  • Grandfield & Dodd added most to Boeing in Q3 2026, an estimated $4.72M increase.
  • Grandfield & Dodd's biggest Q3 2026 reduction was Applied Materials, cutting an estimated $3.25M.
  • Grandfield & Dodd fully exited Omnicom Group in Q3 2026, selling an estimated $268K.
  • Grandfield & Dodd's ten largest holdings make up 39% of its $1.87B portfolio in Q3 2026.
  • Grandfield & Dodd opened 6 new positions and closed 7 in Q3 2026.
  • Grandfield & Dodd's portfolio value fell 1.7% quarter-over-quarter to $1.87B.

Based on Grandfield & Dodd's 13F filing for Q3 2026, filed 29 Oct 2026.